Diatron Expands Clinical Chemistry Test Range for Pictus Analysers
The Diatron Group, global provider of hematology and clinical chemistry analysers, has added 60 new CE marked tests to offer a comprehensive range of high-quality clinical chemistry reagents, which are complemented by calibrators and controls to meet growing laboratory requirements. The new tests include substrates, enzymes, electrolytes, lipids, specific proteins and special tests. Easy-to-use and safe, the tests’ liquid reagents are ready-to-use and load directly onto the Diatron Pictus clinical chemistry analyser range, for which they have been designed and performance-optimised.
Delivering high-quality performance with excellent sensitivity, precision and linearity, all Diatron clinical chemistry reagents are QC-guaranteed. They are manufactured in large production lots in an ISO9001-certified production facility, where they undergo extensive performance testing for each batch and lot to ensure variation is minimised and shelf-life maximised to up to 24 months.
Designed to meet and exceed stringent customer requirements, the new tests perform at the very highest level of all clinical chemistry reagents. Protein assays demonstrate low interference from hook effect or heterophilic antibodies, whilst a unique Ab-latex binding technique enhances quality in Diatron’s immunoturbidimetric-based assays.
Diatron clinical chemistry reagents are highly stable and require minimal calibration runs, so can remain on the analyser between runs and deliver first class performance at all times. Wide assay ranges in many tests ensure fewer sample repeats, saving laboratory time and cost. All tests are also conveniently barcoded for data traceability and eliminating wastage, with calibrators and controls available in appropriate sizes and formats.
When used in combination with Diatron’s Pictus family of highly economical, automated clinical chemistry analysers, Diatron reagents enable automatic reruns and reflex testing. The Pictus range includes the high throughput, fully automated random-access Pictus 700 system and a medium-throughput, bench top automated analyser the Pictus 400. A new analyser, the Pictus 500, is also in development.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance